These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30221835)

  • 21. Rationalized Insights on Causes of Rheumatoid Arthritis in the Elderly and Women: Special Emphasis on Treatment Strategies.
    Srivastava S; Patel S; Singh D; Singh MR
    Crit Rev Ther Drug Carrier Syst; 2017; 34(2):97-147. PubMed ID: 28605317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Towards understanding the role of nanomedicine in targeting TNFR2 in rheumatoid arthritis.
    Lambuk F; Nordin NA; Mussa A; Lambuk L; Ahmad S; Hassan R; Kadir R; Mohamud R; Yahya NK
    Immunology; 2024 Dec; 173(4):622-633. PubMed ID: 39191474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nanomedicines for the treatment of rheumatoid arthritis: State of art and potential therapeutic strategies.
    Wang Q; Qin X; Fang J; Sun X
    Acta Pharm Sin B; 2021 May; 11(5):1158-1174. PubMed ID: 34094826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nanomedicines for chronic non-infectious arthritis: the clinician's perspective.
    Rubinstein I; Weinberg GL
    Nanomedicine; 2012 Sep; 8 Suppl 1():S77-82. PubMed ID: 22640912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advancement in nanotechnology for treatment of rheumatoid arthritis: scope and potential applications.
    Rani R; Raina N; Sharma A; Kumar P; Tulli HS; Gupta M
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Oct; 396(10):2287-2310. PubMed ID: 37166463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanomedicines for chronic non-infectious arthritis: the clinician's perspective.
    Rubinstein I; Weinberg GL
    Maturitas; 2012 Sep; 73(1):68-73. PubMed ID: 22264497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent progress in therapeutic strategies and biomimetic nanomedicines for rheumatoid arthritis treatment.
    Li C; Zheng X; Hu M; Jia M; Jin R; Nie Y
    Expert Opin Drug Deliv; 2022 Aug; 19(8):883-898. PubMed ID: 35760767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of autoreactive T cell in the pathogenesis of rheumatoid arthritis and implications for T cell targeted vaccine therapy.
    Wang D; Li Y; Liu Y; Shi G
    Minerva Med; 2015 Jun; 106(3):157-67. PubMed ID: 26057192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Recent advances in nanocarrier-based drug delivery systems in treatment of rheumatoid arthritis].
    Liang X; Li YL; Bai HT; Zhang QY; Xiao Z; Sun X; Wen WL; Zhang WY; Yang J; Wang R
    Zhongguo Zhong Yao Za Zhi; 2023 Sep; 48(18):4874-4883. PubMed ID: 37802829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The type I IFN system in rheumatoid arthritis.
    Conigliaro P; Perricone C; Benson RA; Garside P; Brewer JM; Perricone R; Valesini G
    Autoimmunity; 2010 Apr; 43(3):220-5. PubMed ID: 20166872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methotrexate-loaded lipid-core nanocapsules are highly effective in the control of inflammation in synovial cells and a chronic arthritis model.
    Boechat AL; de Oliveira CP; Tarragô AM; da Costa AG; Malheiro A; Guterres SS; Pohlmann AR
    Int J Nanomedicine; 2015; 10():6603-14. PubMed ID: 26543364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating Nanomedicines: Obstacles and Advancements.
    Swierczewska M; Crist RM; McNeil SE
    Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanotherapeutics relieve rheumatoid arthritis.
    Yang M; Feng X; Ding J; Chang F; Chen X
    J Control Release; 2017 Apr; 252():108-124. PubMed ID: 28257989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in Soluble CD18 in Murine Autoimmune Arthritis and Rheumatoid Arthritis Reflect Disease Establishment and Treatment Response.
    Kragstrup TW; Jalilian B; Keller KK; Zhang X; Laustsen JK; Stengaard-Pedersen K; Hetland ML; Hørslev-Petersen K; Junker P; Østergaard M; Hauge EM; Hvid M; Vorup-Jensen T; Deleuran B
    PLoS One; 2016; 11(2):e0148486. PubMed ID: 26849368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Promising role of polymeric nanoparticles in the treatment of rheumatoid arthritis.
    Siddique R; Mehmood MH; Haris M; Saleem A; Chaudhry Z
    Inflammopharmacology; 2022 Aug; 30(4):1207-1218. PubMed ID: 35524837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nano-based therapeutics for Rheumatoid arthritis: Recent patents and development.
    Makhija M; Manchanda D; Sharma M
    Recent Pat Nanotechnol; 2023 Sep; ():. PubMed ID: 37691226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-6 in the pathogenesis of rheumatoid arthritis.
    Park JY; Pillinger MH
    Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S4-10. PubMed ID: 17708744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The role of interleukin-6 in rheumatoid arthritis].
    Manfredi M; Benucci M
    Recenti Prog Med; 2008 Jun; 99(6):291-4. PubMed ID: 18710059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A genomics-based systems approach towards drug repositioning for rheumatoid arthritis.
    Xu R; Wang Q
    BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):518. PubMed ID: 27557330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems.
    van Elk M; Murphy BP; Eufrásio-da-Silva T; O'Reilly DP; Vermonden T; Hennink WE; Duffy GP; Ruiz-Hernández E
    Int J Pharm; 2016 Dec; 515(1-2):132-164. PubMed ID: 27725268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.